Targeted removal of PML-RARα protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia

Blood

Volumn 100, Issue 3, 2002, Pages 1008-1013

  Jing, Yongkui ^a   Xia, Lijuan ^a   Waxman, Samuel ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE; RETINOIC ACID;

ARTICLE; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MOLECULAR CLONING; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; RECEPTOR GENE; REMISSION; TARGET CELL; TRANSCRIPTION REGULATION;

EID: 0036682508     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V100.3.1008     Document Type: Article

References (53)

1. Use of alltrans retinoic acid in the treatment of acute promyelocytic leukemia
2. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid)
3. Alltrans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia
4. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17)
5. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy
6. Therapy of acute promyelocytic leukemia: All-trans retinoic acid and beyond
7. Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: Study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells
8. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy
9. Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia
10. Acute promyelocytic leukemia: From genetics to treatment
11. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia
12. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL
13. Acute promyelocytic leukemia: Relieving repression induces remission
14. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia
15. In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications
16. Role of the histone deacetylase complex in acute promyelocytic leukaemia
17. Retinoic acid is required for and potentiates differentiation of acute promyelocytic leukemia cells by nonretinoid agents
18. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: Possible role of the proteasome pathway
19. The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells
20. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo
21. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins
22. Granulocytic differentiation of human NB4 promyelocytic leukemia cells induced by all-trans retinoic acid metabolites
23. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase
24. Initial clinical evaluation of transcription therapy for cancer: All-trans retinoic acid plus phenylbutyrate
25. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), II: Clinical efficacy and pharmacokinetics in relapsed patients
26. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia
27. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
28. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins
29. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3)
30. Alterations in expression, binding to ligand and DNA, and transcriptional activity of rearranged and wild-type retinoid receptors in retinoid-resistant acute promyelocytic leukemia cell lines
31. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system
32. Cloning of a gene (RIG-G) associated with retinoic acid-induced differentiation of acute promyelocytic leukemia cells and representing a new member of a family of interferon-stimulated genes
33. Constitutive expression of the cyclin-dependent kinase inhibitor p21 is transcriptionally regulated by the tumor suppressor protein p53
34. Cloning of the novel human myeloid-cell-specific C/EBP-epsilon transcription factor
35. bfl-1, a bcl-2 homologue, suppresses p53-induced apoptosis and exhibits potent cooperative transforming activity
36. Gene expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells
37. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenicresistant NB4 cells
38. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein
39. Potentiation of retinoic acid-induced differentiation of human acute promyelocytic leukemia NB4 cells by butyric acid, tributyrin, and hexamethylene bisacetamide
40. New synergistic combinations of differentiation inducing agents in the treatment of acute myeloid leukaemia
41. Combinations of retinoic acid with either sodium butyrate, dimethyl sulfoxide, or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukemia cell line HL60
42. Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: A new approach to anti-leukemia therapy
43. CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment
44. Modulation of mRNA expression of a novel human myeloid-selective CCAAT/enhancer binding protein gene (C/EBP epsilon)
45. A critical role for CAAT-enhancer binding protein epsilon in cell cycle arrest and apoptosis during myeloid differentiation
46. C/EBPε mediates myeloid differentiation and is regulated by the CCAAT displacement protein (CDP/cut) in 32Dcl3 cells
47. Maturation sensitive and resistant t(15;17) NB4 cell lines as tools for APL physiopathology: Nomenclature of cells and repertory of their known genetic alterations and phenotypes
48. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients
49. Studies on the clinical efficacy and pharmacokinetics of lowdose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: A comparison with conventional dosage
50. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells
51. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells
52. Oncogenic transcription factors in the human acute leukemias
53. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission